Get in touch

TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole against Black Fungus (Mucormycosis)

Tiefenbacher Group - A scientist wearing safety goggles and a lab coat closely observes equipment in a laboratory focused on patient-centric drug development, surrounded by scientific instruments and glassware.

TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole tablets against Black Fungus (Mucormycosis) in IndiaBlack Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised patients. However, many patients who have survived their COVID-19 infection with the help of external […]

AET Pharma US Inc., Part of Tiefenbacher, approval of Abbreviated New Drug Application (ANDA) for Posaconazole

Tiefenbacher Group - A large group of people, including men and women in formal and colorful traditional attire, stand on a grassy lawn with a modern glass building behind them, reflecting the unity of a family-owned pharmaceutical company dedicated to patient-centric drug development.

AET Pharma US Inc. announces successful approval of Abbreviated New Drug Application (ANDA) for PosaconazoleOn 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole in 100 mg Delayed-Release Tablets. This is another milestone for TIEFENBACHER GROUP in further strengthening its product […]

Get in touch